Automated retrieval of standard diagnostic fetal cardiac ultrasound planes in the second trimester of pregnancy: a prospective evaluation of software.

OBJECTIVE: To evaluate prospectively the performance of software that automatically retrieves, from a three-dimensional (3D) volume of the fetal chest, three diagnostic cardiac planes in the second trimester of pregnancy. METHODS: 3D static volumes of the fetal chest were acquired at the level of the four-chamber view in 72 fetuses between 18 and 23 weeks of gestation. Standardization of 3D volumes was performed in Plane A (the reference plane: four-chamber view) alone. Tomographic ultrasound imaging (TUI) was added to the display of each diagnostic plane. The left ventricular outflow plane (Cardiac plane 1: five-chamber view, aorta), the right ventricular outflow plane (Cardiac plane 2: pulmonary artery) and the abdominal circumference plane (Cardiac plane 3: abdominal circumference, stomach) were retrieved by the software from the 3D volumes and the data were analyzed to determine whether Cardiac planes 1-3 were displayed correctly in each volume. RESULTS: The automated software displayed, in at least one TUI plane, target Cardiac plane 1 in 94.4% of volumes, target Cardiac plane 2 in 91.7% of volumes and target Cardiac plane 3 in 97.2% of volumes. CONCLUSION: Our results validate the concept of automated sonography and its potential clinical applicability.

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.

Interferon beta (IFNbeta) is a first-line therapy for multiple sclerosis (MS). However, some patients experience a decline in efficacy with continued therapy due to the development of anti-IFNbeta neutralizing antibodies (NAb). We investigated the frequency of NAb cross-sectionally in 846 MS patients who were receiving IFNbeta-1b, IFNbeta-1a im, or IFNbeta-1a sc. The frequency of NAb in patients receiving IFNbeta-1a im was lower (5%) than in patients treated with any other form of IFNbeta (22-35%) (P < 0.0001). Binding antibodies (BAb) were measured in 808 patients. The frequency differed significantly between treatment groups, ranging from 45% (IFNbeta-1a im) to 88% (IFNbeta-1b). The proportion of NAb-positive patients within the BAb-positive group differed significantly among treatment groups, ranging between 12% (IFNbeta-1a im) and 51% (IFNbeta-1a sc). The median NAb titer from all IFNbeta-1a-treated patients was higher than from IFNbeta-1b-treated patients (446 versus 171 NU/ mL, P = 0.04). Among NAb-positive patients, the frequency of NAb titers > 100 NU/mL was 71% for IFNbeta-1a compared with 58% for IFNbeta-1b (P = 0.04). Except for conflicting data regarding IFNbeta-1a sc, the results are generally consistent with the literature and together with the differing proportion of NAb-positive patients within the BAb-positive group, provide further insight into the immunogenicity of the IFNbeta preparations.